Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Abvc Biopharma (ABVC) over the last 13 years, with Q3 2025 value amounting to 146.79%.

  • Abvc Biopharma's EBIT Margin fell 691300.0% to 146.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 1121.22%, marking a year-over-year decrease of 2360400.0%. This contributed to the annual value of 923.34% for FY2024, which is 35159000.0% up from last year.
  • Per Abvc Biopharma's latest filing, its EBIT Margin stood at 146.79% for Q3 2025, which was down 691300.0% from 1773.38% recorded in Q2 2025.
  • In the past 5 years, Abvc Biopharma's EBIT Margin ranged from a high of 1773.38% in Q2 2025 and a low of 235539.83% during Q1 2024
  • Moreover, its 5-year median value for EBIT Margin was 1486.05% (2023), whereas its average is 20336.2%.
  • As far as peak fluctuations go, Abvc Biopharma's EBIT Margin crashed by 2000000000bps in 2024, and later skyrocketed by 2000000000bps in 2025.
  • Abvc Biopharma's EBIT Margin (Quarter) stood at 1638.04% in 2021, then plummeted by -132bps to 531.92% in 2022, then tumbled by -4345bps to 23641.34% in 2023, then tumbled by -52bps to 35837.44% in 2024, then skyrocketed by 100bps to 146.79% in 2025.
  • Its EBIT Margin was 146.79% in Q3 2025, compared to 1773.38% in Q2 2025 and 294.95% in Q1 2025.